1
|
Owen C, Banerji V, Johnson N, Gerrie A, Aw A, Chen C, Robinson S. Corrigendum to “Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update” [Leukemia Research 125 (2023) 107016]. Leuk Res 2023; 128:107073. [PMID: 37019803 DOI: 10.1016/j.leukres.2023.107073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
|
2
|
Owen C, Banerji V, Johnson N, Gerrie A, Aw A, Chen C, Robinson S. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leuk Res 2023; 125:107016. [PMID: 36634577 DOI: 10.1016/j.leukres.2023.107016] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 12/22/2022] [Accepted: 01/03/2023] [Indexed: 01/06/2023]
Abstract
Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In 2018, the first unified national guideline in Canada was developed for the front-line treatment of cll that helped guide treatment across the country. As an update in 2022, a group of clinical experts from across Canada came together to provide input and guidance that included new and innovative treatments and approaches that will continue to provide health care professionals with clear guidance on the first-line management of cll. Recommendations were provided in consensus based on available evidence for the first-line treatment of cll.
Collapse
Affiliation(s)
- Carolyn Owen
- Division of Hematology and Hematological Malignancies, Foothills Medical Centre, Calgary, AB T2N 4N2, Canada.
| | - Versha Banerji
- Department of Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada
| | - Nathalie Johnson
- Department of Medicine, Jewish General Hospital, Montréal, QC H3T 1E2, Canada
| | - Alina Gerrie
- Division of Medical Oncology, Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC V5Z 4E6, Canada
| | - Andrew Aw
- Division of Hematology, The Ottawa Hospital, Ottawa, Ontario K1Y 4E9, Canada
| | - Christine Chen
- Department of Medical Oncology, University of Toronto, and Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada
| | - Sue Robinson
- Division of Hematology, Dalhousie University, and qeii Health Sciences Centre, Halifax, NS B3H 2Y9, Canada
| |
Collapse
|
3
|
Ngu H, Parkin S, Villa D, Scott D, Gerrie A, Toze C, Power M, Slack G, Connors J, Song K, Sehn L, Savage K. TCL-323 Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) With Intention for Curative Therapy Incorporating High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT). Clin Lymphoma Myeloma Leuk 2022; 22 Suppl 2:S399-S400. [PMID: 36164129 DOI: 10.1016/s2152-2650(22)01578-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
INTRODUCTION Salvage therapy with high-dose chemotherapy and hematopoietic stem cell transplant (HDC/SCT) is recommended for patients with relapsed/refractory (R/R) PTCL. We evaluated the outcomes of R/R PTCL from the time of first relapse/progression in patients intended for SCT (ITT). METHODS The BC Cancer Lymphoid Cancer Database was reviewed, and patients ≥18 years with R/R PTCLs, such as systemic anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), and PTCL-not otherwise specified (PTCL-NOS), were included. Outcomes were assessed from the time of first relapse/progression and from the time of SCT. RESULTS Of 114 included patients with ITT R/R PTCL, 60% had refractory disease and were more likely to have a high secondary IPI score, poor performance status, or advanced-stage disease. For second-line therapy, the majority received multi-agent chemotherapy (n = 83, 73%) with GDP, (gemcitabine, dexamethasone, and cisplatin) the most used regimen (n = 59, 52%), whereas 15 patients (13%) received novel agents (brentuximab vedotin [BV] = 12; romidepsin=2; pralatrexate=1). The overall response rate (ORR) to second-line therapy was 61% (24% complete response [CR]; 37% partial response [PR]). The ORR to GDP was 61% (17% CR; 44% PR), with higher responses observed in relapsed patients (81% vs. 41%, p=0.002). Seventy-three patients (63%) received HDC/SCT. Those who underwent allo-SCT were younger and more likely to have refractory disease (50% vs. 16%, p=0.001). Third-line therapy was required in 17/67 (25%), including novel agents in 9 cases. The median follow-up for living patients was 6.8 years. The 5-year progression-free survival (PFS) and overall survival (OS) from the time of first relapse/progression were 28% and 38%, respectively. The 5-year PFS from auto and allo-SCT were 34% and 52% (p = 0.3), and 5-year OS were 44% and 67% (p=0.5), respectively. CONCLUSIONS Overall, outcomes for patients with ITT R/R PTCL remain suboptimal, with long-term survival in only one-third of patients; however, over half remained alive at 5 years if they were able to receive an SCT. A third line of therapy may serve as a successful bridge to SCT, and novel agents should be considered. Despite a higher proportion of refractory patients, results are encouraging with allo-SCT.
Collapse
Affiliation(s)
- Henry Ngu
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
| | - Stephen Parkin
- Division of Hematology, University of British Columbia, Vancouver, Canada
| | - Diego Villa
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
| | - David Scott
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
| | - Alina Gerrie
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
| | - Cynthia Toze
- The Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer, Vancouver, Canada
| | - Maryse Power
- The Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer, Vancouver, Canada
| | - Graham Slack
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
| | - Joseph Connors
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
| | - Kevin Song
- The Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer, Vancouver, Canada
| | - Laurie Sehn
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
| | - Kerry Savage
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
| |
Collapse
|
4
|
Lee C, Markarian A, Ladha F, Nakashima L, de Lemos M, Schaff K, Woo S, Gerrie A. Real-world incidence of venetoclax toxicities in British Columbia. J Oncol Pharm Pract 2022:10781552221084616. [DOI: 10.1177/10781552221084616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Introduction Venetoclax is used to treat relapsed/refractory chronic lymphocytic leukemia (r/r CLL). Tumour lysis syndrome (TLS) is a serious toxicity associated with venetoclax, and real-world studies suggest that the incidence may be higher than in clinical trials. The purpose of this study is to describe the incidence of venetoclax toxicities in British Columbia (BC). Methods Retrospective review of electronic medical charts for patient characteristics and clinical outcomes of patients treated with venetoclax for r/r CLL in BC. Patients were classified according to their risk for developing TLS. The incidence of TLS was categorized based on laboratory metrics or clinical diagnosis. Other non-TLS toxicities were also collected. Results Of 33 patients identified, 40%, 33%, and 27% were at low, intermediate, and high risk for TLS, respectively. Laboratory TLS occurred in 1/33 patients (3%), and no clinical TLS was reported. Grade 3 or 4 toxicities occurred in 19/33 patients (58%). Of these, neutropenia was the most common, occurring in 16 patients (84%) followed by thrombocytopenia, which occurred in 8 patients (42%). Conclusions The incidence of TLS in patients treated with venetoclax for r/r CLL in BC was lower than in other real-world studies. Findings may warrant further investigation to determine if the higher incidence of TLS in real-world reports may be mitigated through modifying TLS risk categorization and associated prophylactic measures. Neutropenia was the most common grade 3 or 4 venetoclax toxicity reported, and the incidence in BC is comparable to other centres.
Collapse
|
5
|
Urban R, Chow R, Pickles T, Chan M, Livergant J, Gerrie A, Freeman C, Sehn L, Scott D, Villa D, Savage K, Slack G, Lo A. The Impact of Surveillance Imaging After Curative Intent Radiotherapy for Limited Stage Follicular Lymphoma. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Chahal M, Jiang A, Hayden A, Savage K, Villa D, Scott D, Gerrie A, Lo A, Chan M, Pickles T, Connors J, Sehn L, Freeman C. OUTCOMES AFTER INITIAL REFUSAL OF CURATIVE TREATMENT IN PATIENTS WITH HODGKIN LYMPHOMA IN BRITISH COLUMBIA. Hematol Oncol 2021. [DOI: 10.1002/hon.112_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Chahal
- BC Cancer, Medical Oncology Vancouver Canada
| | - A. Jiang
- British Columbia Cancer Research Centre Biostatistics Vancouver Canada
| | - A. Hayden
- BC Cancer Medical Oncology Surrey Canada
| | - K. Savage
- BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology Vancouver Canada
| | - D. Villa
- BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology Vancouver Canada
| | - D. Scott
- BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology Vancouver Canada
| | - A. Gerrie
- BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology Vancouver Canada
| | - A. Lo
- BC Cancer Division of Radiation Oncology Vancouver Canada
| | - M. Chan
- BC Cancer Division of Radiation Oncology Vancouver Canada
| | - T. Pickles
- BC Cancer Division of Radiation Oncology Vancouver Canada
| | - J. Connors
- BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology Vancouver Canada
| | - L. Sehn
- BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology Vancouver Canada
| | - C. Freeman
- BC Cancer Centre for Lymphoid Cancer and Division of Medical Oncology Vancouver Canada
| |
Collapse
|
7
|
Cherniawsky HM, AlAhwal H, Mourad YA, Forrest D, Gerrie A, Kuchenbauer F, Nantel SH, Narayanan S, Nevill T, Power M, Sanford D, Toze C, White J, Escano L, Sutherland H, Song K. Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population. Clin Lymphoma Myeloma Leuk 2021; 21:476-482. [PMID: 33814336 DOI: 10.1016/j.clml.2021.02.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Revised: 02/21/2021] [Accepted: 02/27/2021] [Indexed: 11/30/2022]
Abstract
Despite improvements in therapy, approximately 5% of patients who undergo autologous stem cell transplantation (ASCT) experience early mortality (EM), death within 1 year of transplant (EM post-ASCT). Such patients tend to have few comorbidities suggesting their EM is owing to aggressive underlying disease. We sought to characterize this ultra-high risk population through a retrospective review of patients with newly diagnosed multiple myeloma (MM) treated with first-line ASCT. Patients who died within 1 year of ASCT were matched for age, sex, and year of transplant in a 1:2 fashion with a control group. Of 962 transplants performed between January 1, 2007, and May 1, 2019, 41 patients (4.3%) died within 1 year of ASCT from MM-related causes. In a multivariate analysis, anemia, hypercalcemia, high-risk cytogenetics, and elevated lactate dehydrogenase were associated with EM post-ASCT. Forty patients (97.6%) received at least 1 novel agent. Most patients with EM post-ASCT received second-line chemotherapy (80.5%), although survival from initiation of second-line chemotherapy was only 2.1 months. The primary reason for not receiving second-line therapy was rapid relapse. Clinical parameters reflecting disease burden, as well as high-risk cytogenetics, are associated with EM post-ASCT. These patients have a dismal overall survival despite significant advances in treatment of patients with relapsed or refractory myeloma. Further study of these ultra-high risk patients is required to improve disease management and may give further insights into the biology of relapse and resistance in myeloma.
Collapse
Affiliation(s)
| | - Hatem AlAhwal
- Department of Hematology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Yasser Abou Mourad
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Donna Forrest
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Alina Gerrie
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Florian Kuchenbauer
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada; Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, Canada
| | - Stephen H Nantel
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Sujaatha Narayanan
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Thomas Nevill
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Maryse Power
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - David Sanford
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Cynthia Toze
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Jennifer White
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Leo Escano
- Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, Canada
| | - Heather Sutherland
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada
| | - Kevin Song
- Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada.
| |
Collapse
|
8
|
Alzahrani M, Power M, Abou Mourad Y, Barnett M, Broady R, Forrest D, Gerrie A, Hogge D, Nantel S, Sanford D, Song K, Sutherland H, Toze C, Nevill T, Narayanan S. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience. Biol Blood Marrow Transplant 2018; 24:1209-1215. [DOI: 10.1016/j.bbmt.2018.02.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2017] [Accepted: 02/08/2018] [Indexed: 01/04/2023]
|
9
|
Kodad SG, Sutherland H, Limvorapitak W, Mourad YA, Barnett MJ, Forrest D, Gerrie A, Hogge DE, Nantel SH, Narayanan S, Nevill T, Power M, Sanford D, Toze C, White J, Broady R, Song K. Outpatient Autologous Stem Cell Transplants for Multiple Myeloma—Analysis of Safety and Outcomes in a Tertiary Care Centre. Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.602] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Parkin S, Wong S, Connors J, Sehn L, Villa D, Gerrie A, Broady R, Power M, Toze C, Song K, Savage K. OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY PERIPHERAL T CELL LYMPHOMA INTENDED FOR STEM CELL TRANSPLANT. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. Parkin
- Division of Hematology; University of British Columbia; Vancouver Canada
| | - S. Wong
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - J.M. Connors
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - L. Sehn
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - D. Villa
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - A. Gerrie
- Leukemia/Bone Marrow Transplant Program of British Columbia; University of British Columbia; Vancouver Canada
| | - R. Broady
- Leukemia/Bone Marrow Transplant Program of British Columbia; University of British Columbia; Vancouver Canada
| | - M. Power
- Leukemia/Bone Marrow Transplant Program of British Columbia; University of British Columbia; Vancouver Canada
| | - C. Toze
- Leukemia/Bone Marrow Transplant Program of British Columbia; University of British Columbia; Vancouver Canada
| | - K. Song
- Leukemia/Bone Marrow Transplant Program of British Columbia; University of British Columbia; Vancouver Canada
| | - K.J. Savage
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| |
Collapse
|
11
|
Kliman D, Barnett M, Broady R, Forrest D, Gerrie A, Hogge D, Nantel S, Narayanan S, Nevill T, Power M, Sanford D, Song K, Sutherland H, Toze C, Abou Mourad Y. Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia. Leuk Lymphoma 2016; 58:909-915. [PMID: 27561638 DOI: 10.1080/10428194.2016.1222376] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
We investigated the utility of a pediatric-inspired protocol in adults aged 18-40 years with standard-risk BCR-ABL negative acute lymphoblastic leukemia (ALL). Retrospective outcomes of 25 patients treated with a pediatric protocol between 2008 and 2014 were compared with 22 similarly aged patients treated with an adult protocol between 2003 and 2008. Twenty-five (100%) and 19 (86%) patients achieved complete remission, respectively. At median follow-up of 36.8 months, 3-year event-free survival was increased in patients on the pediatric protocol at 80% versus 45% (p = .019). There was a trend toward improved overall survival at 80% versus 59% (p = .12). Treatment-related toxicity was not increased despite the increased treatment intensity. Patients with BCR and/or ABL copy number variation demonstrated comparatively poorer outcomes in both cohorts. In our experience with this cohort of patients, pediatric-based protocols are safe and effective, justifying their use in younger adults with ALL.
Collapse
Affiliation(s)
- David Kliman
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Michael Barnett
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Raewyn Broady
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Donna Forrest
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Alina Gerrie
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Donna Hogge
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Stephen Nantel
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Sujaatha Narayanan
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Thomas Nevill
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Maryse Power
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - David Sanford
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Kevin Song
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Heather Sutherland
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Cynthia Toze
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| | - Yasser Abou Mourad
- a Leukemia/BMT Program of British Columbia, Division of Hematology , Vancouver General Hospital, University of British Columbia , Vancouver , BC , Canada
| |
Collapse
|
12
|
Paulson K, Kuruvilla J, Bredeson CN, Cantin G, Couture F, Crump M, Daly A, Foley R, Gerrie A, Hasegawa W, Lachance S, Seftel M, Popradi G, Wall DA, Stewart D. Carmustine-Free Conditioning Regimens Offer Comparable Efficacy to BEAM: The First Report of the Canadian Blood and Marrow Transplant Group Registry. Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Lad DP, Mourad YA, Barnett MJ, Forrest D, Gerrie A, Hogge D, Nantel SH, Narayanan S, Nevill T, Power M, Song K, Sutherland H, Toze C, Broady R. Pre-Transplant Vitamin D Deficiency is Associated with Inferior Overall Survival but not Associated with Relapse Free Survival or Cumulative Incidence of GVHD Post Adult Hematopoietic Cell Transplantation for Hematological Malignancies. Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Hay K, Lee B, Goktepe O, Connors JM, Sehn LH, Savage KJ, Klasa R, Shenkier T, Gerrie A, Villa D. Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2015; 57:276-282. [PMID: 26010123 DOI: 10.3109/10428194.2015.1055480] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Although it is generally regarded appropriate to start chemotherapy promptly after a diagnosis of diffuse large B-cell lymphoma (DLBCL), the optimal time from diagnosis to treatment (TDT) is unknown. A total of 689 patients diagnosed with DLBCL and treated with ≥ 1 cycle of CHOP-R with curative intent during 2003-2008 in British Columbia were identified: 347 (50%) TDT ≤ 4 weeks, 277 (40%) TDT 5-8 weeks, 65 (10%) TDT > 8 weeks. For the respective TDT groups, 5-year OS estimates were 61%, 74%, 63% (p = 0.006); 5-year PFS 57%, 70%, 61% (p = 0.006); and 5-year DSS 64%, 80%, 77% (p <0.001). In multivariate analysis, TDT >8 weeks was associated with worse OS (HR 1.20 (95% CI 1.03, 1.41), p = 0.020), PFS (HR 1.33 (95% CI 1.15, 1.54), p < 0.001), and DSS (HR 1.40 (95% CI 1.10, 1.78), p = 0.006). Clinicians should endeavor to initiate curative chemotherapy as soon as possible after a diagnosis of DLBCL is established.
Collapse
Affiliation(s)
- Kevin Hay
- a Department of Medicine , University of British Columbia , Vancouver , BC , Canada
| | - Benny Lee
- b Faculty of Medicine, University of British Columbia , Vancouver , BC , Canada
| | - Ozge Goktepe
- c Cancer Surveillance & Outcomes, British Columbia Cancer Agency , Vancouver , BC , Canada
| | - Joseph M Connors
- d Division of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer , Vancouver , BC , Canada
| | - Laurie H Sehn
- d Division of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer , Vancouver , BC , Canada
| | - Kerry J Savage
- d Division of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer , Vancouver , BC , Canada
| | - Richard Klasa
- d Division of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer , Vancouver , BC , Canada
| | - Tamara Shenkier
- d Division of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer , Vancouver , BC , Canada
| | - Alina Gerrie
- d Division of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer , Vancouver , BC , Canada.,e Leukemia/Bone Marrow Transplantation Program of BC , Vancouver , BC , Canada
| | - Diego Villa
- d Division of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer , Vancouver , BC , Canada
| |
Collapse
|
15
|
Lavoie JM, Connors JM, Villa D, Klasa RJ, Shenkier TN, Gascoyne RD, Gerrie A, Sehn LH, Savage KJ. The outcome of patients with "nodal" peripheral T-cell lymphomas in a complete response following standard chemotherapy. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.8555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Joseph M. Connors
- British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
| | - Diego Villa
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | | | | | | | - Alina Gerrie
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | | | | |
Collapse
|
16
|
Lee B, Goktepe O, Hay K, Connors JM, Sehn LH, Savage KJ, Shenkier T, Klasa R, Gerrie A, Villa D. Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia. Oncologist 2014; 19:283-90. [PMID: 24569946 DOI: 10.1634/theoncologist.2013-0343] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND We examined the relationship between location of residence at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) and health outcomes in a geographically large Canadian province with publicly funded, universally available medical care. PATIENTS AND METHODS The British Columbia Cancer Registry was used to identify all patients 18-80 years of age diagnosed with DLBCL between January 2003 and December 2008. Home and treatment center postal codes were used to determine urban versus rural status and driving distance to access treatment. RESULTS We identified 1,357 patients. The median age was 64 years (range: 18-80 years), 59% were male, 50% were stage III/IV, 84% received chemotherapy with curative intent, and 32% received radiotherapy. There were 186 (14%) who resided in rural areas, 141 (10%) in small urban areas, 183 (14%) in medium urban areas, and 847 (62%) in large urban areas. Patient and treatment characteristics were similar regardless of location. Five-year overall survival (OS) was 62% for patients in rural areas, 44% in small urban areas, 53% in medium urban areas, and 60% in large urban areas (p = .018). In multivariate analysis, there was no difference in OS between rural and large urban area patients (hazard ratio [HR]: 1.0; 95% confidence interval [CI]: 0.7-1.4), although patients in small urban areas (HR: 1.4; 95% CI: 1.0-2.0) and medium urban areas (HR: 1.4; 95% CI: 1.0-1.9) had worse OS than those in large urban areas. CONCLUSION Place of residence at diagnosis is associated with survival of patients with DLBCL in British Columbia, Canada. Rural patients have similar survival to those in large urban areas, whereas patients living in small and medium urban areas experience worse outcomes.
Collapse
Affiliation(s)
- Benny Lee
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver, British Columbia, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Mak V, Ip D, Mang O, Dalal C, Huang S, Gerrie A, Gillan T, Ramadan KM, Toze C, Au WY. Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008. Leuk Lymphoma 2013; 55:824-7. [DOI: 10.3109/10428194.2013.827785] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
18
|
Gerrie A, Marsh J, Lipton JH, Messner H, Gupta V. Marrow transplantation for severe aplastic anemia with significant renal impairment. Bone Marrow Transplant 2007; 39:311-3. [PMID: 17237828 DOI: 10.1038/sj.bmt.1705583] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|